Cardio Diagnostics Holdings Reports Fiscal Year 2025 Results with Revenue Decline and Improved Net Loss

**Cardio Diagnostics Holdings, Inc. Reports Fiscal Year 2025 Results**

Cardio Diagnostics Holdings, Inc., a medical technology company focused on cardiovascular disease, reported its financial results for the fiscal year ended December 31, 2025. The company generated revenue of $14,825, a decrease from the $34,890 reported in the previous fiscal year. This decline was attributed to the conclusion of a specific heart attack prevention testing initiative with Family Medicine Specialists. The company's net loss for the year was $6.49 million, an improvement compared to the $8.38 million loss in 2024.

Operating expenses for the year totaled $6.49 million, with sales and marketing expenses at $766,888, research and development expenses at $641,212, and general and administrative expenses at $5.02 million. The decrease in general and administrative expenses was primarily due to a decrease in stock compensation expenses and director and officer insurance expense. The company's cash position at the end of the year was $5.11 million, a decrease from $7.82 million at the end of the previous year.

During the year, Cardio Diagnostics continued to focus on driving adoption of its clinical solutions, particularly among providers, channel partners, and employers. The company also expanded internationally, partnering with organizations in India. Furthermore, the company made progress in setting up its laboratory facility to comply with Clinical Laboratory Improvement Amendments (CLIA) standards. The company sold 292,495 shares of common stock at various amounts per share to investors for gross proceeds totaling $3.9 million before deducting sales commissions of $96,994 to the placement agent.

Looking ahead, Cardio Diagnostics plans to leverage its CPT PLA codes to expand reimbursement efforts, develop additional products for stroke, heart failure, and diabetes, and expand its clinical and health economics evidence portfolio. The company also intends to offer laboratory services via its CLIA laboratory, expand adoption of its products across key channels, explore additional market opportunities domestically and internationally, scale its internal operations, and pursue potential strategic partnerships or acquisitions. Subsequent to December 31, 2025, the Company sold 1,133,418 shares of Common Stock for gross proceeds totaling $3,788,174 under the At-the-Market Issuance Sales Agreement as of the date of this report.